iHCK-37

**iHCK-37** is a potent and selective small molecule inhibitor of hematopoietic cell kinase (HCK), a member of the Src family of tyrosine kinases. It has a Ki value of 0.22 μM for HCK inhibition and has demonstrated strong antiproliferative effects against acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines[1][2][4][7][8][9]. iHCK-37 inhibits HCK-dependent signaling pathways including PI3K/AKT, MAPK/ERK, and mTOR, which are implicated in cell survival, proliferation, migration, and drug resistance in leukemias[2][3][7][8]. Mechanistically, it promotes leukemia cell death, cell-cycle arrest, and apoptosis in malignant cells while sparing normal hematopoietic cells[7][8]. Beyond single-agent activity, iHCK-37 shows additive effects in combination with standard chemotherapeutics (5-Azacytidine, Cytarabine) in vitro and in vivo[2][7]. These studies support iHCK-37 as a preclinical candidate for the development of anti-leukemia and anti-HIV agents; it also blocks HIV-1 replication with an EC50 of 12.9 μM[1][4].

Other names

iHCK-37iHCK37iHCK 37ASN05260065ASN-05260065ASN 05260065